Peginterferon alfa-2b did not prolong time to first occurrence of either clinical decompensation, hepatocellular carcinoma, liver transplant, or death.
The previous HALT-C trial demonstrated that low-dose, maintenance peginterferon alfa-2a did not reduce hepatic decompensation or hepatocellular carcinoma (HCC) rates or improve survival in patients infected with hepatitis C virus (HCV) who had advanced fibrosis and previous nonresponse to therapy (JW Gastroenterol Dec 5 2008). Now, the EPIC3 study (Evaluation of PegInron in Control of Hepatitis C Cirrhosis) has revisited peginterferon therapy for reducing cirrhosis-related clinical events in patients with HCV infection and cirrhosis.
In an international, multicenter, industry-sponsored, open-label trial, investigators randomized 626 HCV-infected patients with biopsy-confirmed cirrhosis, no evidence of HCC, and a previous failure to respond t…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose